title: Treatment options for newly diagnosed patients with chronic myeloid leukemia.
abstract: Chronic myeloid leukemia (CML) is characterized by a 9:22 translocation resulting in production of a chimeric BCR-ABL fusion protein that has constitutive tyrosine kinase activity and drives leukemic transformation. Imatinib mesylate, a selective inhibitor of BCR-ABL, has been introduced into clinical trials with favorable toxicity and impressive activity at all disease stages. In a phase III study of diagnosed chronic phase CML, imatinib mesylate was superior to interferon plus cytarabine in cytogenetic response, freedom from disease progression, and tolerability. Hematopoietic stem cell transplantation remains the only established cure for CML. Recent reports show continued improvements with survivals after matched sibling grafts greater than 80% at 3 to 5 years. Therefore, recent advances in conventional and transplant therapy have improved treatment options for newly diagnosed patients. Sensitive and specific monitoring techniques developed for CML may help further refine treatment with regard to using these and other emerging therapies.
authors.affiliation: University of Colorado Health Sciences Center, 4200 East Ninth Avenue B 190, Denver, CO 80262, USA.
authors.forename: Lori J
authors.initials: LJ
authors.lastname: Maness
authors.forename: Peter A
authors.initials: PA
authors.lastname: McSweeney
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001549:Benzamides; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000097:blood; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D015337:Multicenter Studies as Topic; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D011379:Prognosis; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl